Corbus Pharmaceuticals Holdings, Inc. (CRBP) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Win.
29/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 5 wins, 7 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseCRBP / S&P -0.11% / 15.20% |
LoseCRBP / S&P CRBP unavailable / 15.00% |
LoseCRBP / S&P 28.90% / 50.40% |
| 2026-Q12/3 |
WinCRBP / S&P 15.36% / -4.33% |
LoseCRBP / S&P CRBP unavailable / 11.30% |
WinCRBP / S&P 36.67% / 27.70% |
| 2025-Q41/3 |
LoseCRBP / S&P -35.65% / 2.65% |
LoseCRBP / S&P CRBP unavailable / 9.00% |
WinCRBP / S&P 62.09% / 13.40% |
| 2025-Q32/3 |
WinCRBP / S&P 83.33% / 8.12% |
LoseCRBP / S&P CRBP unavailable / 4.61% |
WinCRBP / S&P 17.56% / 13.45% |
| 2025-Q21/3 |
WinCRBP / S&P 29.94% / 10.94% |
LoseCRBP / S&P CRBP unavailable / 4.83% |
LoseCRBP / S&P -18.13% / 10.63% |
| 2025-Q10/3 |
LoseCRBP / S&P -55.00% / -4.27% |
LoseCRBP / S&P CRBP unavailable / 4.98% |
LoseCRBP / S&P -39.48% / 10.57% |
| 2024-Q40/3 |
LoseCRBP / S&P -42.80% / 2.41% |
LoseCRBP / S&P CRBP unavailable / 5.25% |
LoseCRBP / S&P -64.83% / 6.15% |
| 2024-Q30/3 |
LoseCRBP / S&P -54.41% / 5.89% |
LoseCRBP / S&P CRBP unavailable / 5.89% |
LoseCRBP / S&P -58.15% / 6.11% |
| 2024-Q21/3 |
WinCRBP / S&P 15.32% / 4.28% |
LoseCRBP / S&P CRBP unavailable / 5.38% |
LoseCRBP / S&P -47.36% / 5.12% |
| 2024-Q11/3 |
WinCRBP / S&P 549.67% / 10.56% |
LoseCRBP / S&P CRBP unavailable / 5.71% |
LoseCRBP / S&P -42.79% / 5.59% |
| 2023-Q40/3 |
LoseCRBP / S&P -10.39% / 11.69% |
LoseCRBP / S&P CRBP unavailable / 6.81% |
LoseCRBP / S&P 1.97% / 7.78% |
| 2023-Q30/3 |
LoseCRBP / S&P -14.03% / -3.27% |
LoseCRBP / S&P CRBP unavailable / 7.52% |
LoseCRBP / S&P -39.38% / -5.03% |
| 2023-Q20/3 |
LoseCRBP / S&P 7.84% / 8.74% |
LoseCRBP / S&P CRBP unavailable / 9.50% |
LoseCRBP / S&P -32.60% / -8.57% |
| 2023-Q11/3 |
WinCRBP / S&P 118.32% / 7.50% |
LoseCRBP / S&P CRBP unavailable / 10.77% |
LoseCRBP / S&P CRBP unavailable / -15.69% |
| 2022-Q40/3 |
LoseCRBP / S&P -32.73% / 7.56% |
LoseCRBP / S&P CRBP unavailable / 11.88% |
LoseCRBP / S&P CRBP unavailable / -17.99% |
| 2022-Q30/3 |
LoseCRBP / S&P -34.52% / -4.88% |
LoseCRBP / S&P CRBP unavailable / 13.47% |
LoseCRBP / S&P CRBP unavailable / -1.41% |
| 2022-Q20/3 |
LoseCRBP / S&P -52.63% / -16.10% |
LoseCRBP / S&P CRBP unavailable / 13.71% |
LoseCRBP / S&P CRBP unavailable / 11.04% |
| 2022-Q10/3 |
LoseCRBP / S&P -13.64% / -4.60% |
LoseCRBP / S&P -91.72% / 15.97% |
LoseCRBP / S&P CRBP unavailable / 42.23% |
| 2021-Q40/3 |
LoseCRBP / S&P -39.61% / 11.03% |
LoseCRBP / S&P -77.61% / 15.00% |
LoseCRBP / S&P CRBP unavailable / 96.40% |
| 2021-Q30/3 |
LoseCRBP / S&P -44.26% / 0.58% |
LoseCRBP / S&P -73.69% / 10.77% |
LoseCRBP / S&P CRBP unavailable / 69.42% |
| 2021-Q20/3 |
LoseCRBP / S&P -7.11% / 8.55% |
LoseCRBP / S&P -62.93% / 6.58% |
LoseCRBP / S&P CRBP unavailable / 51.81% |
| 2021-Q11/3 |
WinCRBP / S&P 57.60% / 6.17% |
LoseCRBP / S&P -92.16% / -1.06% |
LoseCRBP / S&P CRBP unavailable / 7.39% |
| 2020-Q40/3 |
LoseCRBP / S&P -30.56% / 12.15% |
LoseCRBP / S&P -89.11% / -3.72% |
LoseCRBP / S&P CRBP unavailable / -33.42% |
| 2020-Q30/3 |
LoseCRBP / S&P -78.55% / 8.93% |
LoseCRBP / S&P -83.51% / -2.04% |
LoseCRBP / S&P CRBP unavailable / -27.10% |
| 2020-Q21/3 |
WinCRBP / S&P 60.11% / 20.54% |
LoseCRBP / S&P -78.79% / -0.46% |
LoseCRBP / S&P CRBP unavailable / -27.11% |
| 2020-Q12/3 |
WinCRBP / S&P -4.03% / -19.60% |
WinCRBP / S&P 525.62% / 3.47% |
LoseCRBP / S&P CRBP unavailable / -14.75% |
| 2019-Q42/3 |
WinCRBP / S&P 12.11% / 9.07% |
WinCRBP / S&P 649.51% / 5.36% |
LoseCRBP / S&P CRBP unavailable / 2.99% |
| 2019-Q31/3 |
LoseCRBP / S&P -29.73% / 1.70% |
WinCRBP / S&P 1126.18% / 5.02% |
LoseCRBP / S&P CRBP unavailable / 0.21% |
| 2019-Q21/3 |
LoseCRBP / S&P -0.29% / 4.30% |
WinCRBP / S&P 1207.43% / 6.64% |
LoseCRBP / S&P CRBP unavailable / 8.65% |
| 2019-Q12/3 |
WinCRBP / S&P 19.01% / 13.65% |
WinCRBP / S&P 174.57% / 8.12% |
LoseCRBP / S&P CRBP unavailable / 14.29% |
| 2018-Q41/3 |
LoseCRBP / S&P -22.65% / -13.52% |
WinCRBP / S&P 97.62% / 9.05% |
LoseCRBP / S&P CRBP unavailable / 18.23% |
| 2018-Q31/3 |
WinCRBP / S&P 49.50% / 7.71% |
LoseCRBP / S&P 2.81% / 10.21% |
LoseCRBP / S&P CRBP unavailable / 19.06% |
| 2018-Q20/3 |
LoseCRBP / S&P -17.21% / 3.43% |
LoseCRBP / S&P -5.85% / 9.03% |
LoseCRBP / S&P CRBP unavailable / 14.46% |
| 2018-Q10/3 |
LoseCRBP / S&P -14.08% / -0.76% |
LoseCRBP / S&P -25.34% / 7.68% |
LoseCRBP / S&P CRBP unavailable / 12.46% |
| 2017-Q41/3 |
LoseCRBP / S&P -0.70% / 6.64% |
WinCRBP / S&P 27.66% / 7.03% |
LoseCRBP / S&P CRBP unavailable / 13.82% |
| 2017-Q32/3 |
WinCRBP / S&P 13.49% / 4.48% |
WinCRBP / S&P 48.20% / 5.68% |
LoseCRBP / S&P CRBP unavailable / 17.57% |
| 2017-Q21/3 |
LoseCRBP / S&P -23.64% / 3.09% |
WinCRBP / S&P 108.00% / 4.83% |
LoseCRBP / S&P CRBP unavailable / 17.74% |
| 2017-Q11/3 |
LoseCRBP / S&P -2.37% / 6.07% |
WinCRBP / S&P 168.76% / 3.67% |
LoseCRBP / S&P CRBP unavailable / 13.32% |
| 2016-Q42/3 |
WinCRBP / S&P 24.45% / 3.82% |
WinCRBP / S&P 194.80% / 2.09% |
LoseCRBP / S&P CRBP unavailable / 7.05% |
| 2016-Q31/3 |
WinCRBP / S&P 127.09% / 3.85% |
LoseCRBP / S&P CRBP unavailable / 0.20% |
LoseCRBP / S&P CRBP unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | CRBP total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 18.78% | 20.78% |
| Annualized return | 18.78% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | CRBP total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -70.79% | 83.14% |
| Annualized return | -21.82% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | CRBP total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -91.17% | 319.30% |
| Annualized return | -21.55% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |